inclusion criteria: * male or non-pregnant female adults, ≥18 years old of age at the time of randomization; * participants should have at least one of covid-19 risk factor; * participants should have at least 2 covid-19 related symptoms; * has symptoms consistent with covid-19 as determined by the investigator with onset ≤7 days before randomization; * first positive sars-cov-2 viral infection tested (pcr or antigen-based diagnostic tests) in samples collected ≤3 days prior to start of the infusion; * participants are currently not hospitalized; * participant (or legal authorized representative) has signed the icf before any clinical activity related to scta01 trial; * women with childbearing potential must agree to use effective contraceptive methods during the study period; * patient should not participate in other clinical studies related to covid-19 or sars-cov-2 infection.

inclusion criteria: * male or non-pregnant female adults, ≥18 years old of age at the time of randomization; * participants should have at least one of covid-19 risk factor; * participants should have at least 2 covid-19 related symptoms; * has symptoms consistent with covid-19 as determined by the investigator with onset ≤7 days before randomization; * first positive sars-cov-2 viral infection tested (pcr or antigen-based diagnostic tests) in samples collected ≤3 days prior to start of the infusion; * participants are currently not hospitalized; * participant (or legal authorized representative) has signed the icf before any clinical activity related to scta01 trial; * women with childbearing potential must agree to use effective contraceptive methods during the study period; * patient should not participate in other clinical studies related to covid-19 or sars-cov-2 infection.

inclusion criteria: - male or non-pregnant female adults, ≥18 years old of age at the time of randomization; - participants should have at least one of covid-19 risk factor; - participants should have at least 2 covid-19 related symptoms; - has symptoms consistent with covid-19 as determined by the investigator with onset ≤7 days before randomization; - first positive sars-cov-2 viral infection tested (pcr or antigen-based diagnostic tests) in samples collected ≤3 days prior to start of the infusion; - participants are currently not hospitalized; - participant (or legal authorized representative) has signed the icf before any clinical activity related to scta01 trial; - women with childbearing potential must agree to use effective contraceptive methods during the study period; - patient should not participate in other clinical studies related to covid-19 or sars-cov-2 infection.

inclusion criteria: - male or non-pregnant female adults, ≥18 years old of age at the time of randomization; - participants should have at least one of covid-19 risk factor; - participants should have at least 2 covid-19 related symptoms; - has symptoms consistent with covid-19 as determined by the investigator with onset ≤7 days before randomization; - first positive sars-cov-2 viral infection tested (pcr or antigen-based diagnostic tests) in samples collected ≤3 days prior to start of the infusion; - participants are currently not hospitalized; - participant (or legal authorized representative) has signed the icf before any clinical activity related to scta01 trial; - women with childbearing potential must agree to use effective contraceptive methods during the study period; - patient should not participate in other clinical studies related to covid-19 or sars-cov-2 infection.